Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Garfield Heights, Ohio Clinical Trials

A listing of Garfield Heights, Ohio clinical trials actively recruiting patient volunteers.

RESULTS

Found (57) clinical trials

Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian Fallopian Tube Or Peritoneal Cancer

Pegylated liposomal doxorubicin (PLD; e.g., Doxil®, Lipodox™) will be administered intravenously on Day 1 and EGEN-001 will be administered intraperitoneally on Day 1, 8, 15, and 22 of a 28-day cycle to determine: - The maximum tolerated dose (MTD) and dose limiting toxicities (DLTs) of EGEN-001 when administered in combination ...

Phase

5.42 miles

Learn More »

Mesenchymal Stem Cells in Early Rheumatoid Arthritis

This is a prospective, multicenter (with two performance sites under the auspices of Case Western Reserve University Clinical and Translational Science Award (CWRU CTSA) at University Hospitals and at MetroHealth Medical Center), double-blind, placebo-controlled, interventional study to evaluate the safety and efficacy of allogeneic mesenchymal stem cells (MSCs) infusion in ...

Phase

5.42 miles

Learn More »

A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors

To better understand the safety and tolerability of ALKS 4230 in humans

Phase

6.32 miles

Learn More »

Vincristine Sulfate Liposome Injection (Marqibo ) in Combination With UK ALL R3 Induction Chemotherapy for Children Adolescents and Young Adults With Relapsed ALL

This study will utilize Marqibo as a replacement for standard vincristine in combination with UK ALL R3 induction for children with relapsed ALL. The hypothesis is that the incorporation of Marqibo with combination chemotherapy will be safe and feasible. In the context of this pilot study, overall outcomes and efficacy ...

Phase

6.32 miles

Learn More »

Study of IV CBL0137 in Previously Treated Hematological Subjects

Part 1 of the study will evaluate the safety and pharmacology of a range of CBL0137 doses administered IV in subjects with previously treated lymphomas, including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), or Hodgkin lymphoma (HL). Part 2 of the study provides cohort expansion ...

Phase

6.32 miles

Learn More »

A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab) Gemcitabine Lenalidomide or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma

The drug being tested in this study is called TAK-659. TAK-659 is being tested to treat people who have advanced non-Hodgkin lymphoma. This study will determine the MTD or RP2D for TAK-659 in combination with bendamustine, bendamustine + rituximab, gemcitabine, lenalidomide, and ibrutinib. The study will enroll approximately 100 participants. ...

Phase

6.32 miles

Learn More »

Study of REGN2810 and REGN1979 in Patients With Lymphoma

This is an open-label, multicenter, dose escalation study of REGN2810 and REGN1979 in patients with lymphoma. The study treatment period will be from 6 to 12 months, depending on how an individual patient responds to treatment. The follow-up period will be 6 months for all patients.

Phase

6.32 miles

Learn More »

Dose-finding Pharmacokinetics and Safety of VABOMERE in Pediatric Subjects With Bacterial Infections

In the current era of increased resistance to extended spectrum cephalosporins, carbapenem antimicrobial agents are frequently the antibiotics of "last defense" for the most resistant pathogens in serious infections, including those found in complicated Urinary Tract Infections (cUTI). The recent dissemination of serine carbapenemases (e.g. KPC) in Enterobacteriaceae in many ...

Phase

6.32 miles

Learn More »

Pharmacokinetic and Safety Study of Ceftolozane/Tazobactam in Pediatric Participants Receiving Antibiotic Therapy for Proven or Suspected Gram-negative Infection or for Peri-operative Prophylaxis (MK-7625A-010)

Screening assessments will occur within 48 hours of study drug administration (Day 1). Baseline assessments will be performed following eligibility verification based on screening assessments. Participants will be monitored for safety 24 hours post study drug infusion. The site will contact the participant and/or parent (or appropriate legal representative) via ...

Phase

6.32 miles

Learn More »

A Study of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients

The purpose of the study is to evaluate the pharmacokinetics (PK), safety and tolerability of multiple doses of intravenous (IV) and oral isavuconazonium sulfate administered daily in pediatric patients. The PK data will be utilized to establish a pediatric population PK model of isavuconazole, the active moiety of isavuconazonium sulfate.

Phase

6.32 miles

Learn More »